A Phase 1, Randomized, Open-Label, Sponsor-Open, Two-Sequence, Two-Period Crossover Study to Investigate the Bioequivalence of a Single Subcutaneous Dose of BMN 111 Administered Using Either a Vial and Syringe or Injector Pen in Healthy Adult Participants
Latest Information Update: 16 Oct 2023
At a glance
- Drugs Vosoritide (Primary)
- Indications Achondroplasia; Short stature
- Focus Pharmacokinetics
- Sponsors BioMarin Pharmaceutical
Most Recent Events
- 10 Oct 2023 Status changed from recruiting to discontinued, as further optimization of the approach to achieve bioequivalence is required. The study termination was not due to any patient safety concerns.
- 18 Apr 2023 New trial record